Compugen discovers novel drug targets through a unique, predictive, computational process that combines human biology derived from genome analysis with disease information derived from analysis of vast amount of proprietary and publicly available data. This process, which is generally applicable to many fields of medical interest, usually results in multiple drug target candidates. Our comprehensive data analysis therefore enables us to often identify first-in-class drug target candidates, which are difficult to identify using traditional screening approaches.

Built on the understanding and mathematical modeling of biological phenomena, our discovery process is flexible enough to be applicable to a wide range of indications and diseases. Our computational tools were tested and optimized for over a decade and have been successfully applied to many biological phenomena, resulting in findings which were published in dozens of first-tier peer reviewed scientific journals. The applicability of the infrastructure was demonstrated internally in multiple therapeutic and diagnostic areas and, in contrast to traditional discovery methodologies, demonstrated significant advantages in terms of cost, time and most importantly, probability of successful validation.

Our in silico discovery process is followed by a therapeutically focused validation phase, in which the novel candidates undergo an extensive set of experiments to confirm the in silico prediction and provide additional detailed data as to their relevance and potential as drug targets for therapeutic development.


Predictive Discovery

Our process for in silico discovery of novel drug targets

Target Discovery

An overview of our process for the discovery of B7/CD28-like and other immunomodulators

Target Validation

Therapeutically focused drug target validation pipeline


COM701 Demonstrates Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Malignancies

Ryan Sullivan, Drew Rasco, Emerson Lim, Manish Sharma, Dale Shepard, Amita Patnaik, Erika Hamilton, Gini Fleming, Kyri Papadopoulos, Adam ElNaggar, Adeboye Henry Adewoye, Bartosz Chmielowski, Ecaterina Dumbrava, Dan Vaena
Apr 2020

A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Malignancies

RJ Sullivan, EA Lim, M Sharma, DR Shepard, A Patnaik, EP Hamilton, GI Fleming, K Papadopoulos, A ElNaggar, AH Adewoye, J Hunter, EE Ileana-Dumbrava, B Chmielowski, DW Rasco, DA Vaena
Feb 2020

Activation of Human NK Cells Modulates Expression of the Inhibitory Reception PVRIG

Jessica li, Sarah Whelan, Spencer C. Liang, Maya F. Kotturi, Mark White, Kyle Hansen, John Hunter, Joseph A. Trapani, Paul J. Neeson
Dec 2019

Phase 1 Study of COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Tumors

E. Ileana Dumbrava, G. Fleming, E. Hamilton, R. Sullivan, A Patnaik, K. Papadopoulos, A. ElNaggar, J. Hunter, J. Olweny, A. Adewoye, B. Chmielowski, D. Shepard, M. Sharma, E. Lim, D. Vaena, D. Rasco
Nov 2019